Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PeptiDream Inc. (4587.T)
JPY999.30
-7.20 (-0.72%)
JP JPX Healthcare Biotechnology
Address
3-25-23 Tonomachi 210-0821
Kawasaki, JP
Kawasaki, JP
CEO
Patrick Crawford Reid
Website
peptidream.com
IPO
2013-06-12
ISIN JP3836750004
Also trades on
Other OTC · PPTDF (USD)
Tokyo Stock Exchange · 4587.T (JPY)
Description
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY999.30
-7.20 (-0.72%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
990.9K
Beta
0.37
Float Shares
95.16M
Free Float %
74.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.59% | -4.70% | -6.27% | -27.16% | -32.19% | -31.77% | -35.40% | -38.69% | -77.05% | -63.19% | -3.83% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
999.30
DCF (Unlevered)
2,391.98
+139.4%
DCF (Levered)
1,889.61
+89.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
83% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.71
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-60.3% Q1'26: +12.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-125.1% Q1'26: +16.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-30.1% Q1'26: -27.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-26.9% Q1'26: -23.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-12.5% ★ Q1'26: -8.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.4% ★ Q1'26: -0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-5.98× Q1'26: -6.92× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 6 EPS Ana. |
Dec 2027 7 Rev. Ana. 6 EPS Ana. |
Dec 2028 7 Rev. Ana. 6 EPS Ana. |
Dec 2029 3 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.47B
est: 2.46B (+0.5%)
|
4.33B
est: 4.32B (+0.2%)
|
4.90B
est: 4.80B (+2.0%)
|
6.43B
est: 7.46B (-13.9%)
|
7.22B
est: 7.22B (+0.0%)
|
2.07B
est: 7.22B (-71.2%)
|
11.68B
est: 10.76B (+8.5%)
|
9.42B
est: 11.22B (-16.0%)
|
26.85B
est: 25.23B (+6.4%)
|
28.71B
est: 55.42B (-48.2%)
|
46.68B
est: 46.07B (+1.3%)
|
18.52B
est: 18.63B (-0.6%)
|
43.33B
28.20B – 64.45B
+132.5% YoY
|
45.14B
29.81B – 62.24B
+4.2% YoY
|
50.65B
50.62B – 50.67B
+12.2% YoY
|
61.50B
40.33B – 88.08B
+21.4% YoY
|
79.02B
51.81B – 113.17B
+28.5% YoY
|
| EBITDA |
1.49B
est: 1.12B (+33.5%)
|
2.69B
est: 1.96B (+37.0%)
|
2.69B
est: 2.18B (+23.1%)
|
3.49B
est: 3.39B (+3.0%)
|
4.10B
est: 3.28B (+25.0%)
|
-1.26B
est: 3.28B (-138.5%)
|
7.56B
est: 4.89B (+54.6%)
|
4.68B
est: 5.10B (-8.2%)
|
11.32B
est: 11.47B (-1.3%)
|
9.61B
est: 17.80B (-46.0%)
|
23.64B
est: 14.79B (+59.8%)
|
-2.85B
est: 5.98B (-147.6%)
|
13.91B
9.06B – 20.69B
+132.5% YoY
|
14.49B
9.57B – 19.99B
+4.2% YoY
|
16.26B
16.25B – 16.27B
+12.2% YoY
|
19.75B
12.95B – 28.28B
+21.4% YoY
|
25.37B
16.64B – 36.34B
+28.5% YoY
|
| EBIT |
1.39B
est: 960.74M (+44.8%)
|
2.55B
est: 1.69B (+51.2%)
|
2.49B
est: 1.87B (+33.0%)
|
2.98B
est: 2.91B (+2.3%)
|
3.58B
est: 2.81B (+27.2%)
|
-1.77B
est: 2.81B (-163.0%)
|
6.99B
est: 4.20B (+66.5%)
|
4.05B
est: 4.38B (-7.5%)
|
9.35B
est: 9.84B (-5.0%)
|
7.18B
est: 13.49B (-46.8%)
|
21.39B
est: 11.22B (+90.7%)
|
-4.97B
est: 4.54B (-209.7%)
|
10.55B
6.86B – 15.69B
+132.5% YoY
|
10.99B
7.26B – 15.15B
+4.2% YoY
|
12.33B
12.32B – 12.34B
+12.2% YoY
|
14.97B
9.82B – 21.44B
+21.4% YoY
|
19.23B
12.61B – 27.55B
+28.5% YoY
|
| Net Income |
1.00B
est: 970.74M (+3.4%)
|
1.58B
est: 1.97B (-19.8%)
|
1.89B
est: 2.53B (-25.2%)
|
2.34B
est: 2.83B (-17.6%)
|
2.77B
est: 2.91B (-4.8%)
|
-976.93M
est: 2.91B (-133.6%)
|
4.45B
est: 4.28B (+4.0%)
|
2.57B
est: 4.49B (-42.6%)
|
7.55B
est: 5.15B (+46.7%)
|
3.04B
est: 21.69B (-86.0%)
|
15.01B
est: 18.52B (-18.9%)
|
-3.75B
est: -1.39B (-170.3%)
|
14.26B
2.23B – 18.36B
+1,127.9% YoY
|
14.02B
1.27B – 17.37B
-1.7% YoY
|
15.62B
3.40B – 22.74B
+11.5% YoY
|
18.43B
10.18B – 28.78B
+17.9% YoY
|
28.63B
15.82B – 44.72B
+55.4% YoY
|
| SGA |
272.80M
est: 430.96M (-36.7%)
|
464.80M
est: 755.93M (-38.5%)
|
676.93M
est: 839.75M (-19.4%)
|
748.43M
est: 1.31B (-42.7%)
|
—
est: 1.26B (-100.0%)
|
648.86M
est: 1.26B (-48.6%)
|
1.01B
est: 1.88B (-46.5%)
|
2.59B
est: 1.96B (+31.9%)
|
5.83B
est: 4.41B (+32.1%)
|
6.67B
est: 14.54B (-54.1%)
|
8.59B
est: 12.09B (-29.0%)
|
7.47B
est: 4.89B (+52.9%)
|
11.37B
7.40B – 16.91B
+132.5% YoY
|
11.84B
7.82B – 16.33B
+4.2% YoY
|
13.29B
13.28B – 13.30B
+12.2% YoY
|
16.14B
10.58B – 23.11B
+21.4% YoY
|
20.73B
13.59B – 29.69B
+28.5% YoY
|
| EPS |
9.18
est: 7.48 (+22.7%)
|
14.23
est: 15.20 (-6.4%)
|
16.54
est: 19.48 (-15.1%)
|
19.35
est: 21.83 (-11.4%)
|
22.42
est: 22.42 (+0.0%)
|
-7.80
est: 22.42 (-134.8%)
|
35.40
est: 32.95 (+7.4%)
|
19.96
est: 34.57 (-42.3%)
|
58.19
est: 38.10 (+52.7%)
|
23.41
est: 167.34 (-86.0%)
|
115.85
est: 135.49 (-14.5%)
|
-28.99
est: -10.74 (-169.8%)
|
72.00
17.25 – 141.99
+770.2% YoY
|
76.13
9.81 – 134.36
+5.7% YoY
|
107.59
26.28 – 175.83
+41.3% YoY
|
142.50
78.72 – 222.58
+32.4% YoY
|
221.40
122.31 – 345.82
+55.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-22.98B
OE per share TTM
-177.88
Owner's Yield
-16.19%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
62.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 76 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | OneAscent International Equity ETF OAIM | 2.02% | 7.45M | 0.95% |
| 2 | MUFG Japan Small Cap Active ETF MJSC | 0.23% | 51.5K | 0.85% |
| 3 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.05% | 272.6K | 0.58% |
| 4 | iShares MSCI Japan Small-Cap ETF SCJ | 0.05% | 121.5K | 0.50% |
| 5 | Schwab International Small-Cap Equity ETF SCHC | 0.02% | 1.25M | 0.06% |
| 6 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.02% | 39.6K | 0.83% |
| 7 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.02% | 2.39M | 0.40% |
| 8 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.02% | 2.45M | 0.06% |
| 9 | iShares International Small-Cap Equity Factor ETF ISCF | 0.01% | 90.9K | 0.24% |
| 10 | Amundi Japan TOPIX II UCITS ETF EUR Hedged Dist JPNH.PA | 0.01% | 96.3K | 0.45% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-8.01M
Shares Outstanding
128.49M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Patrick Crawford Reid | President, Chief Executive Officer & Representative Director | 211M | — |
| Kiyofumi Kaneshiro | Chief Financial Officer, Executive Vice President & Director | 178M | — |
| Christian Cunningham | Chief Scientific Officer | — | male |
| Masato Murakami | Executive VP of Radiopharmaceuticals Business, Chief Medical Officer & Director | — | male |
| Yen Ting Chen | Head of Business Development & Alliance Management | — | — |
| Yuko Okimoto | IR & Public Relations Director | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4587.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
